KUALA LUMPUR, Sept 17 -- Sun Genomics, the direct-to-consumer custom probiotics and gut health company, has closed US$9.25 million in Series A funding. (US$1 = RM4.131)
Sun Genomics will use the funding round to support growth in the custom probiotics market, scale delivery across the United States, enter international markets and propel the publication of its studies in partnership with leading academic institutions.
According to a statement, the funding was led by Pangaea Ventures with new investments from Orion Fund, managed by K3 Ventures and Emerging Technologies Partners.
Additional investors include Danone Manifesto Ventures, SOSV, Human Longevity and Nascita Ventures.
In addition to the Series A close, Sun Genomics announces Dr Jack Gilbert, PhD, as medical and scientific adviser, and Mayank Goel as growth vice-president.
At the University of California, San Diego Center of Microbiome Innovation, Dr Gilbert uses molecular analysis to test fundamental hypotheses in microbial ecology.
On the other hand, prior to Sun Genomics, Goel led growth marketing and analytics at two successfully acquired travel startups – HotelTonight (acquired by Airbnb) and Pillow (acquired by Vrbo, Expedia Group).
He has created data-driven personalised services leading to growing user retention and revenues. Goel brings a unique combination of growth strategy and data analytics to help Sun Genomics become the leader in custom probiotics.
-- BERNAMA
No comments:
Post a Comment